Barclays initiates coverage on Novo Nordisk (NYSE: NVO) with a Underweight rating.Analyst Dr. Emmanuel Papadakis comments "Novo has run hard ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE